Analyst Price Target is $6.63
▲ +179.54% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Selecta Biosciences in the last 3 months. The average price target is $6.63, with a high forecast of $10.00 and a low forecast of $3.50. The average price target represents a 179.54% upside from the last price of $2.37.
Current Consensus is
The current consensus among 5 contributing investment analysts is to buy stock in Selecta Biosciences. This Buy consensus rating has held steady for over two years.
Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.